Provided By GlobeNewswire
Last update: Aug 7, 2025
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
Read more at globenewswire.comNASDAQ:PMVP (10/24/2025, 3:16:37 PM)
1.605
+0.02 (+1.58%)
Find more stocks in the Stock Screener


